Cargando…

Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study

OBJECTIVE: To evaluate the clinical efficacy of concurrent chemoradiotherapy (CCRT) using daily low-dose cisplatin for cervical cancer. METHODS: Fifty-one patients with locally advanced cervical cancer (FIGO stage IB2, bulky IIA, IIB-IVA) who were treated with CCRT as primary therapy at Kurume Unive...

Descripción completa

Detalles Bibliográficos
Autores principales: Ushijima, Kimio, Fujiyoshi, Keizo, Kawano, Kouichiro, Tsuda, Naotake, Nishio, Shin, Eto, Hidehiro, Kamura, Toshiharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644685/
https://www.ncbi.nlm.nih.gov/pubmed/23653826
http://dx.doi.org/10.3802/jgo.2013.24.2.108
_version_ 1782268468859502592
author Ushijima, Kimio
Fujiyoshi, Keizo
Kawano, Kouichiro
Tsuda, Naotake
Nishio, Shin
Eto, Hidehiro
Kamura, Toshiharu
author_facet Ushijima, Kimio
Fujiyoshi, Keizo
Kawano, Kouichiro
Tsuda, Naotake
Nishio, Shin
Eto, Hidehiro
Kamura, Toshiharu
author_sort Ushijima, Kimio
collection PubMed
description OBJECTIVE: To evaluate the clinical efficacy of concurrent chemoradiotherapy (CCRT) using daily low-dose cisplatin for cervical cancer. METHODS: Fifty-one patients with locally advanced cervical cancer (FIGO stage IB2, bulky IIA, IIB-IVA) who were treated with CCRT as primary therapy at Kurume University Hospital between 2000 and 2007 were retrospectively reviewed. CCRT consisted of 5 mg/m(2)/day of cisplatin 5 days per week, and external beam radiotherapy (EBRT) administrated to whole pelvis to 45-50.6 Gy. High-dose-rate intracavitary brachytherapy was delivered in a single dose of 4-5 Gy at point A, once a week after 20-30 Gy of EBRT. RESULTS: The median follow-up duration was 42 months (range, 5 to 116 months). The overall response rate was 94.1%. Five year overall survival rate was 71.5% and 46.2% in stage I or II, and stage III or IVA, respectively. During follow-up period, 30 recurrences (58.8%) were found, the local failure rate was 39%, and distant failure rate was 35.2%, and both (local and distant) were 15.7%. Hematological toxicities were the most frequent acute toxicities. Grade 3 and 4 neutropenia was observed in 37.3%. Late intestinal toxicities appeared in 7 cases (13.7%), which occurred between 6 and 114 months after treatment. Four cases required bowel surgery. CONCLUSION: CCRT using daily low-dose cisplatin was tolerable and showed favorable initial response as the primary therapy for locally advanced uterine cervical cancer. But there was no remarkable long-term benefit for patients' survival or local disease control in this study. The incidence of late intestinal toxicity still requires further investigation.
format Online
Article
Text
id pubmed-3644685
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
record_format MEDLINE/PubMed
spelling pubmed-36446852013-05-07 Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study Ushijima, Kimio Fujiyoshi, Keizo Kawano, Kouichiro Tsuda, Naotake Nishio, Shin Eto, Hidehiro Kamura, Toshiharu J Gynecol Oncol Original Article OBJECTIVE: To evaluate the clinical efficacy of concurrent chemoradiotherapy (CCRT) using daily low-dose cisplatin for cervical cancer. METHODS: Fifty-one patients with locally advanced cervical cancer (FIGO stage IB2, bulky IIA, IIB-IVA) who were treated with CCRT as primary therapy at Kurume University Hospital between 2000 and 2007 were retrospectively reviewed. CCRT consisted of 5 mg/m(2)/day of cisplatin 5 days per week, and external beam radiotherapy (EBRT) administrated to whole pelvis to 45-50.6 Gy. High-dose-rate intracavitary brachytherapy was delivered in a single dose of 4-5 Gy at point A, once a week after 20-30 Gy of EBRT. RESULTS: The median follow-up duration was 42 months (range, 5 to 116 months). The overall response rate was 94.1%. Five year overall survival rate was 71.5% and 46.2% in stage I or II, and stage III or IVA, respectively. During follow-up period, 30 recurrences (58.8%) were found, the local failure rate was 39%, and distant failure rate was 35.2%, and both (local and distant) were 15.7%. Hematological toxicities were the most frequent acute toxicities. Grade 3 and 4 neutropenia was observed in 37.3%. Late intestinal toxicities appeared in 7 cases (13.7%), which occurred between 6 and 114 months after treatment. Four cases required bowel surgery. CONCLUSION: CCRT using daily low-dose cisplatin was tolerable and showed favorable initial response as the primary therapy for locally advanced uterine cervical cancer. But there was no remarkable long-term benefit for patients' survival or local disease control in this study. The incidence of late intestinal toxicity still requires further investigation. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2013-04 2013-04-05 /pmc/articles/PMC3644685/ /pubmed/23653826 http://dx.doi.org/10.3802/jgo.2013.24.2.108 Text en Copyright © 2013. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ushijima, Kimio
Fujiyoshi, Keizo
Kawano, Kouichiro
Tsuda, Naotake
Nishio, Shin
Eto, Hidehiro
Kamura, Toshiharu
Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
title Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
title_full Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
title_fullStr Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
title_full_unstemmed Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
title_short Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
title_sort concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644685/
https://www.ncbi.nlm.nih.gov/pubmed/23653826
http://dx.doi.org/10.3802/jgo.2013.24.2.108
work_keys_str_mv AT ushijimakimio concurrentchemoradiotherapywithlowdosedailycisplatinforhighriskuterinecervicalcanceralongtermfollowupstudy
AT fujiyoshikeizo concurrentchemoradiotherapywithlowdosedailycisplatinforhighriskuterinecervicalcanceralongtermfollowupstudy
AT kawanokouichiro concurrentchemoradiotherapywithlowdosedailycisplatinforhighriskuterinecervicalcanceralongtermfollowupstudy
AT tsudanaotake concurrentchemoradiotherapywithlowdosedailycisplatinforhighriskuterinecervicalcanceralongtermfollowupstudy
AT nishioshin concurrentchemoradiotherapywithlowdosedailycisplatinforhighriskuterinecervicalcanceralongtermfollowupstudy
AT etohidehiro concurrentchemoradiotherapywithlowdosedailycisplatinforhighriskuterinecervicalcanceralongtermfollowupstudy
AT kamuratoshiharu concurrentchemoradiotherapywithlowdosedailycisplatinforhighriskuterinecervicalcanceralongtermfollowupstudy